Kingfisher Capital LLC Sells 200 Shares of Novo Nordisk A/S (NYSE:NVO)

Kingfisher Capital LLC lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 6.9% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 2,693 shares of the company’s stock after selling 200 shares during the period. Kingfisher Capital LLC’s holdings in Novo Nordisk A/S were worth $321,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Financial Counselors Inc. increased its holdings in shares of Novo Nordisk A/S by 1.1% during the third quarter. Financial Counselors Inc. now owns 11,009 shares of the company’s stock worth $1,311,000 after purchasing an additional 115 shares during the period. MayTech Global Investments LLC boosted its position in Novo Nordisk A/S by 14.1% in the third quarter. MayTech Global Investments LLC now owns 254,552 shares of the company’s stock valued at $30,309,000 after buying an additional 31,475 shares in the last quarter. FORA Capital LLC acquired a new position in Novo Nordisk A/S in the 3rd quarter worth about $5,309,000. CreativeOne Wealth LLC increased its position in Novo Nordisk A/S by 158.7% in the 3rd quarter. CreativeOne Wealth LLC now owns 20,463 shares of the company’s stock valued at $2,437,000 after acquiring an additional 12,552 shares during the period. Finally, Cravens & Co Advisors LLC grew its position in shares of Novo Nordisk A/S by 1.6% in the 3rd quarter. Cravens & Co Advisors LLC now owns 8,097 shares of the company’s stock valued at $964,000 after buying an additional 128 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $106.13 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market cap of $476.26 billion, a P/E ratio of 34.35, a P/E/G ratio of 1.37 and a beta of 0.42. The stock has a 50 day simple moving average of $113.22 and a two-hundred day simple moving average of $128.18. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15.

Analyst Ratings Changes

A number of equities research analysts have recently commented on NVO shares. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BMO Capital Markets cut their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Buy” and an average price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.